Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03352947 | Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma(INTERIM) | completed | Phase 2 | 79 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01726738 | LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | completed | Phase 2 | 17 | UNC Lineberger Comprehensive Cancer Center |
| 1 |
| Nov 23, 2020 |
| clinicaltrials |
| NCT00471887 | Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma | completed | Phase 2 | 32 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT01328535 | Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 25 | Mayo ClinicOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT00525031 | Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients | completed | Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT02363283 | Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2020 | clinicaltrials |
| NCT01512251 | BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma | completed | Phase 1 / Phase 2 | 8 | University of California, San FranciscoOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT00039325 | Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma | completed | Phase 1 / Phase 2 | 28 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00300612 | Vaccine Treatment for Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | 6 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01682213 | Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation | completed | Phase 2 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2020 | clinicaltrials |
| NCT01704287 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) | completed | Phase 2 | 540 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 18, 2020 | clinicaltrials |
| NCT00005971 | Flavopiridol in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 17 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 9, 2020 | clinicaltrials |
| NCT02354690 | Vemurafenib and TIL Therapy for Metastatic Melanoma | completed | Phase 1 / Phase 2 | 13 | Inge Marie SvaneOTHER | 1 | Mar 23, 2020 | clinicaltrials |
| NCT01363206 | Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma(GIPI) | completed | Phase 2 | 29 | Lynn E. Spitler, MDOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT00062491 | Study of Karenitecin (BNP1350) to Treat Malignant Melanoma | completed | Phase 2 | 46 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT01449279 | Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy | completed | Phase 2 | 22 | Stanford UniversityOTHER | 1 | Mar 2, 2020 | clinicaltrials |
| NCT01266603 | High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI | completed | Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 19, 2020 | clinicaltrials |
| NCT01413191 | Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2020 | clinicaltrials |
| NCT02583516 | Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma | completed | Phase 2 | 70 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01941927 | Trametinib With GSK2141795 in BRAF Wild-type Melanoma | completed | Phase 2 | 20 | Adil DaudOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT02537600 | Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis(CONVERCE) | completed | Phase 2 | 43 | Center Eugene MarquisOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02379195 | Peginterferon and TIL Therapy for Metastatic Melanoma | completed | Phase 1 / Phase 2 | 12 | Inge Marie SvaneOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02158520 | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 24 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT02424916 | Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study(MelSort) | completed | Phase 1 / Phase 2 | 7 | Nantes University HospitalOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02094872 | Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic | completed | Phase 2 | 49 | Yale UniversityOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT04180774 | Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer | completed | Phase 1 / Phase 2 | 80 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT00590824 | Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma | completed | Phase 2 | 23 | University of Wisconsin, MadisonOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT02014441 | Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec | completed | Phase 2 | 61 | AmgenINDUSTRY | 2 | Nov 20, 2019 | clinicaltrials |
| NCT00109863 | Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma | completed | Phase 2 | 14 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT01196416 | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma | completed | Phase 1 / Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Nov 18, 2019 | clinicaltrials |
| NCT01136967 | An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma | completed | Phase 2 | 182 | Eisai Inc.INDUSTRY | 4 | Nov 13, 2019 | clinicaltrials |
| NCT00314093 | RFT-5-dgA in Patients With Metastatic Melanoma | completed | Phase 2 | 41 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01883323 | Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma | completed | Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01551459 | A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma(SUAVE) | completed | Phase 2 | 124 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Oct 29, 2019 | clinicaltrials |
| NCT00254397 | Melanoma Vaccine With Peptides and Leuprolide | completed | Phase 2 | 98 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT03007823 | High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02768207 | A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma | completed | Phase 2 | 40 | Hoffmann-La RocheINDUSTRY | 2 | Aug 28, 2019 | clinicaltrials |
| NCT01876212 | Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma | completed | Phase 2 | 15 | Walter J. StorkusOTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT01107665 | Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma | completed | Phase 2 | 60 | University of California, IrvineOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01636882 | CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)(CALMext) | completed | Phase 2 | 16 | ViralyticsINDUSTRY | 1 | Jul 9, 2019 | clinicaltrials |
| NCT01227551 | A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )(CALM) | completed | Phase 2 | 57 | ViralyticsINDUSTRY | 1 | Jul 5, 2019 | clinicaltrials |
| NCT02306850 | Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma(NeoPembroMel) | completed | Phase 2 | 10 | St. Louis UniversityOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT00301067 | Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT01258855 | Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | May 10, 2019 | clinicaltrials |
| NCT01290536 | Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases | completed | Phase 2 | 42 | Nicholas Fidelman, MDOTHER | 0 | Mar 1, 2019 | clinicaltrials |
| NCT01100528 | Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance | completed | Phase 2 | 38 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT01124734 | High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma | completed | Phase 2 | 17 | Milton S. Hershey Medical CenterOTHER | 1 | Feb 12, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Dec 8, 2020source: clinicaltrials